BPC-157: what the published research covers

PlatinumLongevity.co sells BPC-157 for laboratory research use only. This page summarizes the published literature. It is not guidance for human use.

What it is

BPC-157 is a synthetic peptide of 15 amino acids. Its sequence is GEPPPGKPADDAGLV (Staresinic et al., 2003). Researchers describe it as a partial sequence of a larger protein, body protection compound, first isolated from human gastric juice (Chang et al., 2011).

PubChem lists the free peptide as C62H98N16O22, with a molecular weight of 1419.5 g/mol. Its CAS number there is 137525-51-0 (PubChem). The acetate salt carries a separate CAS number, 1628202-19-6, on the Cayman Chemical product sheet. Check which form a certificate of analysis describes.

What has been studied

Most BPC-157 research is preclinical. A 2025 systematic review screened 544 records and kept 36 studies. Of those, 35 were preclinical and one was clinical (Vasireddi et al., 2025).

Animal and cell work

In a 2003 rat study, the Achilles tendon was cut and left with a gap. Rats given BPC-157 showed higher load to failure and better Achilles functional index scores than saline controls (Staresinic et al., 2003). The same paper reported that BPC-157 alone did not change the growth of cultured tendon cells.

A 2011 in vitro study used fibroblasts from rat Achilles tendon. BPC-157 did not change cell proliferation. It did increase outgrowth from tendon explants, cell survival under hydrogen peroxide stress, and cell migration. The authors linked these effects to the FAK-paxillin signaling pathway (Chang et al., 2011).

Reviews describe effects on blood vessel growth, nitric oxide signaling, and inflammation across many rodent models (McGuire et al., 2025).

Human work

A 2025 review counted three human pilot reports. They covered knee pain, interstitial cystitis, and intravenous tolerance (McGuire et al., 2025).

The knee report was a retrospective chart review at one Florida clinic. Of 17 patients, 16 were reached by phone. Twelve had received BPC-157 alone by intra-articular administration, and 11 of those 12 reported improvement. There was no control group and no standard outcome tool (Lee and Padgett, 2021).

The intravenous pilot enrolled two adults who had received BPC-157 before. Blood markers for heart, liver, kidney, thyroid, and glucose showed no measurable change. No side effects were reported (Lee and Burgess, 2025).

Regulatory status in the US, October 2026

BPC-157 has no FDA approval (Vasireddi et al., 2025). Its compounding status changed several times in 2026.

• FDA now lists BPC-157 among substances whose nominations were withdrawn. FDA notes a possible immunogenicity risk and limited safety data (FDA).
• On April 15, 2026, FDA announced it would remove 12 peptides, including BPC-157, from Category 2. That removal does not make them eligible for 503A compounding (Frier Levitt, April 2026).
• FDA presented BPC-157 to its Pharmacy Compounding Advisory Committee on July 23, 2026, even though both nominations were withdrawn (FDA briefing).
• The committee voted 8 yes, 6 no, 1 abstain to recommend it for the 503A bulks list. FDA scientists had recommended against it (McDermott, July 2026).
• The vote is advisory. As of September 17, 2026, FDA still had to complete formal rulemaking (Frier Levitt, September 2026).

On August 24, 2026, FDA sent warning letters to sellers of "research use only" peptides. In one letter, FDA said website evidence showed the products were intended for human use, despite the labels (FDA warning letter). That letter named tesamorelin and PT-141, not BPC-157.

What is unknown or contested

• Human evidence. No randomized controlled trial in humans was found in these reviews. McGuire and colleagues write that rigorous, large-scale trials are lacking.
• Human safety. The 2025 systematic review found no clinical safety data. FDA says it lacks enough information to know whether the peptide would cause harm in humans.
• Reporting. The knee study is summarized differently across sources. The systematic review reports it as 7 of 12 patients with relief for over six months.
• Product quality. The systematic review notes that unregulated manufacturing and contamination are possible sources of harm.
• Pharmacokinetics. Preclinical data suggest liver metabolism, kidney clearance, and a half-life under 30 minutes (Vasireddi et al., 2025).

Handling notes for a lab

Cayman Chemical supplies BPC-157 acetate as a solid. Its product sheet gives storage at -20°C and stability of at least four years in that form. The sheet labels the material for research only, not for human or veterinary use (Cayman Chemical). Follow the certificate of analysis for your lot, and record the salt form in your lab notes.

Lot documentation and specifications are on the product page, BPC-157 at PlatinumLongevity.co.